Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis

Table 1 Characteristics of eligible studies

Year	First author	Sample size	Mean age (year)	Patient with BCa	Non-invasive	Assay method	Cut-off criteria	TP	FP	FN	TN	Sensitivity	Specificity	AUC-ROC
2000	Sanchez-Carbayo M	355	NR	130	62	Solid-phase chemiluminescent immunometric assay	52.8 μg/L	104	57	26	168	0.800	0.747	0.823
2002	Eissa S	215	56.5	100	29	ELISA	198 ng/mgCr	83	20	17	95	0.830	0.826	0.836
2003	Mutlu N	130	NR	75	51	Solid-phase chemiluminescent immunometric assay	43.4 ng/mgCr	54	10	21	45	0.720	0.821	0.804
2005	Menendez V	123	NR	68	52	DPC immulite autoanalyzer	25.6 μg/L	53	11	15	44	0.78	0.80	NR
2008	Li LY	167	62.5	126	112	Solid-phase chemiluminescent immunometric assay	67.8 μg/L	49	8	5	60	0.914	0.878	0.896
2010	Eissa S	240	57.76	100	NR	ELISA	186.5 ng/mgCr	82	22	18	118	0.820	0.843	0.920
2011	Eissa S	240	56.60	132	NR	ELISA	41.7 ng/mg BSA	106	42	26	66	0.803	0.612	0.806
2013	Shen ZJ	147	NR	85	64	Gold immunochromatography	Test line of Fn test paper colored	62	13	23	49	0.729	0.790	NR

ISSN: 1477-7819